Market Research Logo

Epstein-Barr Viral Infections - Pipeline Review, H2 2016

Epstein-Barr Viral Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Epstein-Barr Viral Infections - Pipeline Review, H2 2016’, provides an overview of the Epstein-Barr Viral Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Epstein-Barr Viral Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epstein-Barr Viral Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Epstein-Barr Viral Infections
  • The report reviews pipeline therapeutics for Epstein-Barr Viral Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Epstein-Barr Viral Infections therapeutics and enlists all their major and minor projects
  • The report assesses Epstein-Barr Viral Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Epstein-Barr Viral Infections
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Epstein-Barr Viral Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Epstein-Barr Viral Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Epstein-Barr Viral Infections Overview
Therapeutics Development
Pipeline Products for Epstein-Barr Viral Infections - Overview
Pipeline Products for Epstein-Barr Viral Infections - Comparative Analysis
Epstein-Barr Viral Infections - Therapeutics under Development by Companies
Epstein-Barr Viral Infections - Therapeutics under Investigation by Universities/Institutes
Epstein-Barr Viral Infections - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Epstein-Barr Viral Infections - Products under Development by Companies
Epstein-Barr Viral Infections - Products under Investigation by Universities/Institutes
Epstein-Barr Viral Infections - Companies Involved in Therapeutics Development
Arno Therapeutics, Inc.
Cell Medica Limited
Epiphany Biosciences, Inc.
Genocea Biosciences, Inc.
Humabs BioMed SA
Molplex Ltd.
Omeros Corporation
Savoy Pharmaceuticals, Inc.
Theravectys SA
Vironika, LLC
ViroStatics srl
Epstein-Barr Viral Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AR-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for EBV Associated PTLD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Systemic Lupus Erythematosus and Epstein-Barr Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Viral Infections Post-HSCT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target Calcineurin A for EBV associated post transplant B cell lymphoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMD-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Epstein-Barr virus (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Epstein-Barr virus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Epstein-Barr Viral Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MVA vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Infectious Mononucleosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit EBNA1 for Epstein-Barr Virus (EBV) Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target GPR183 for Osteoporosis and Epstein-Barr Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit EBNA1 for Epstein-Barr Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Epstein-Barr Virus and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
valomaciclovir stearate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Viroprev - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Epstein-Barr Viral Infections - Dormant Projects
Epstein-Barr Viral Infections - Product Development Milestones
Featured News & Press Releases
Mar 25, 2014: University of Birmingham launches trial to fight cancer caused by a common virus
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Epstein-Barr Viral Infections, H2 2016
Number of Products under Development for Epstein-Barr Viral Infections - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Epstein-Barr Viral Infections - Pipeline by Arno Therapeutics, Inc., H2 2016
Epstein-Barr Viral Infections - Pipeline by Cell Medica Limited, H2 2016
Epstein-Barr Viral Infections - Pipeline by Epiphany Biosciences, Inc., H2 2016
Epstein-Barr Viral Infections - Pipeline by Genocea Biosciences, Inc., H2 2016
Epstein-Barr Viral Infections - Pipeline by Humabs BioMed SA, H2 2016
Epstein-Barr Viral Infections - Pipeline by Molplex Ltd., H2 2016
Epstein-Barr Viral Infections - Pipeline by Omeros Corporation, H2 2016
Epstein-Barr Viral Infections - Pipeline by Savoy Pharmaceuticals, Inc., H2 2016
Epstein-Barr Viral Infections - Pipeline by Theravectys SA, H2 2016
Epstein-Barr Viral Infections - Pipeline by Vironika, LLC, H2 2016
Epstein-Barr Viral Infections - Pipeline by ViroStatics srl, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Epstein-Barr Viral Infections - Dormant Projects, H2 2016
List of Figures
Number of Products under Development for Epstein-Barr Viral Infections, H2 2016
Number of Products under Development for Epstein-Barr Viral Infections - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report